Imperial College London

DrNeloferSyed

Faculty of MedicineDepartment of Brain Sciences

Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 5292n.syed

 
 
//

Location

 

E506Burlington DanesHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

113 results found

Pazmandi J, O'Neill KS, Scheck AC, Szlosarek PW, Woolf EC, Brooks KS, Syed Net al., 2015, The ketogenic diet alters the expression of microRNAs that play key roles in tumor development, 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Abaitua F, Przystal J, Hajitou A, Syed Net al., 2015, Arginine deprivation using ADI-PEG20 leads to regression of an ASS1-ve intracranial GBM tumor in mice and potentiates gamma irradiation of ASS1+ve GBM in vitro, 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Yata T, Lee ELQ, Suwan K, Syed N, Asavarut P, Hajitou Aet al., 2015, Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors, Molecular Cancer, Vol: 14, ISSN: 1476-4598

Journal article

Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M, McNeish IAet al., 2015, Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control, MOLECULAR ONCOLOGY, Vol: 9, Pages: 791-805, ISSN: 1574-7891

Journal article

Langer J, Elustondo FA, Chan ECY, Antti H, Want E, ONeill K, Syed Net al., 2014, METABOLOMIC ANALYSIS OF GLIOBLASTOMA MULTIFORME UPON ARGININE DEPRIVATION TREATMENT, NEURO-ONCOLOGY, Vol: 16, ISSN: 1522-8517

Journal article

Channathodiyil P, Kardooni H, Khozoie C, Nelofer S, Darling J, Morris M, Warr Tet al., 2014, EPIGENETIC INACTIVATION OF ARGININE BIOSYNTHESIS PATHWAY IN PAEDIATRIC HIGH GRADE GLIOMA, NEURO-ONCOLOGY, Vol: 16, ISSN: 1522-8517

Journal article

Abaitua F, Crook T, O'Neill K, Syed Net al., 2014, TARGETING COLLAGEN REGULATION IN GLIOBLASTOMA MULTIFORME, NEURO-ONCOLOGY, Vol: 16, ISSN: 1522-8517

Journal article

Qiao B, Oneill K, Syed N, 2014, SCOTIN EXPRESSION AND SURVIVAL IN GBM, Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517

Conference paper

Langer JK, Chan ECY, Antti H, Want E, ONeill K, Syed Net al., 2014, METABOLOMIC ANALYSIS OF GLIOBLASTOMA MULTIFORME UPON ARGININE DEPRIVATION TREATMENT, Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517

Conference paper

Abaitua F, Crook T, O'Neill K, Syed Net al., 2014, TARGETING COLLAGEN REGULATION IN GLIOBLASTOMA MULTIFORME, Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517

Conference paper

Asavarut P, O'Neill K, Syed N, Hajitou Aet al., 2014, Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma., Ther Deliv, Vol: 5, Pages: 975-990

The incipient development of gene therapy for cancer has fuelled its progression from bench to bedside in mere decades. Of all malignancies that exist, gliomas are the largest class of brain tumors, and are renowned for their aggressiveness and resistance to therapy. In order for gene therapy to achieve clinical success, a multitude of barriers ranging from glioma tumor physiology to vector biology must be overcome. Many viral gene delivery systems have been subjected to clinical investigation; however, with highly limited success. In this review, the current progress and challenges of gene therapy for malignant glioma are discussed. Moreover, we highlight the hybrid adeno-associated virus and bacteriophage vector as a potential candidate for targeted gene delivery to brain tumors.

Journal article

Hatzimichael E, Syed N, Lo Nigro C, Crook Tet al., 2014, A blood test to identify when melanoma metastasizes: a reality for melanoma management?, Melanoma Manag, Vol: 1, Pages: 11-14

Journal article

Hatzimichael E, Syed N, Lo Nigro C, Rao B, Crook Tet al., 2014, How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, Vol: 14, Pages: 639-642, ISSN: 1473-7159

Journal article

Allen MD, Phuong L, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu B-W, Bomalaski JS, Jackson RC, Lu Y-J, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li C-F, Szlosarek PWet al., 2014, Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging, CANCER RESEARCH, Vol: 74, Pages: 896-907, ISSN: 0008-5472

Journal article

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook Tet al., 2013, Methylated Tissue Factor Pathway Inhibitor 2 (TFP12) DNA in Serum Is a Biomarker of Metastatic Melanoma, JOURNAL OF INVESTIGATIVE DERMATOLOGY, Vol: 133, Pages: 1278-1285, ISSN: 0022-202X

Journal article

Przystal JM, Umukoro E, Stoneham CA, Yata T, O'Neill K, Syed N, Hajitou Aet al., 2013, Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage, MOLECULAR ONCOLOGY, Vol: 7, Pages: 55-66, ISSN: 1574-7891

Journal article

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli Fet al., 2013, Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma., Cell Death & Disease, Vol: 4, ISSN: 2041-4889

Arginine deprivation, either by nutritional starvation or exposure to ADI-PEG20, induces adaptive transcriptional upregulation ofASS1 and ASL in glioblastoma multiforme ex vivo cultures and cell lines. This adaptive transcriptional upregulation is blocked byneoplasia-specific CpG island methylation in either gene, causing arginine auxotrophy and cell death. In cells with methylatedASS1 or ASL CpG islands, ADI-PEG20 initially induces a protective autophagic response, but abrogation of this by chloroquineaccelerates and potentiates cytotoxicity. Concomitant methylation in the CpG islands of both ASS1 and ASL, observed in asubset of cases, confers hypersensitivity to ADI-PEG20. Cancer stem cells positive for CD133 and methylation in the ASL CpGisland retain sensitivity to ADI-PEG20. Our results show for the first time that epigenetic changes occur in both of the two keygenes of arginine biosynthesis in human cancer and confer sensitivity to therapeutic arginine deprivation. We demonstrate thatmethylation status of the CpG islands, rather than expression levels per se of the genes, predicts sensitivity to argininedeprivation. Our results suggest a novel therapeutic strategy for this invariably fatal central nervous system neoplasm for whichwe have identified robust biomarkers and which overcomes the limitations to conventional chemotherapy imposed by the blood/brain barrier.

Journal article

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJS, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook Tet al., 2012, The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma, British Journal of Cancer, Vol: 107, Pages: 1423-1432, ISSN: 1532-1827

Journal article

Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM, Lo Nigro C, Schmid Pet al., 2012, EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER, 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: OXFORD UNIV PRESS, Pages: 532-533, ISSN: 0923-7534

Conference paper

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook Tet al., 2012, Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBP delta) CpG island in breast cancer is associated with metastatic relapse, BRITISH JOURNAL OF CANCER, Vol: 107, Pages: 732-738, ISSN: 0007-0920

Journal article

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li C-F, Joel S, Fitzgibbon J, Chen L-T, Szlosarek PWet al., 2012, Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis, CELL DEATH & DISEASE, Vol: 3, ISSN: 2041-4889

Journal article

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro Cet al., 2012, MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer, ORAL ONCOLOGY, Vol: 48, Pages: 602-607, ISSN: 1368-8375

Journal article

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook Tet al., 2012, NT5E CpG island methylation is a favourable breast cancer biomarker, British Journal of Cancer, Vol: 107, Pages: 75-83, ISSN: 1532-1827

BACKGROUND: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In thelight of existing preclinical and clinical data, we studied NT5E (50-nucleotidase, ecto) expression and NT5E CpG island methylation inbreast cancer.METHODS: We used RT–PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines andprimary and breast carcinomas.RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series,patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P ¼ 0.003, OR ¼ 0.34, 95%CI: 0.17–0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patientsprogressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primarytumours (P ¼ 0.01, OR ¼ 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS)(P ¼ 0.001, HR ¼ 2.7) and overall survival (OS) (P ¼ 0.001, HR ¼ 3). The favourable prognostic value of NT5E methylation wasconfirmed in oestrogen receptor negative (P ¼ 0.011, HR ¼ 3.27, 95% CI: 1.31–8.12) and in triple negative cases (P ¼ 0.004;HR ¼ 6.2, 95% CI: 1.9–20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whosetumours were positive for NT5E CpG island methylation: DFS (P ¼ 0.0016, HR ¼ 5.1, 95% CI: 1.8–14.37) and OS (P ¼ 0.0005,HR ¼ 7.4, 95% CI: 2.416–23.08).CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker

Journal article

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook Tet al., 2012, Methylation of the calcium channel regulatory subunit alpha 2 delta-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas, British Journal of Cancer, Vol: 107, Pages: 375-381, ISSN: 1532-1827

BACKGROUND: Calcium is an important intracellular messenger that mediates many biological processes that are relevant to themalignant process. Calcium ion channels are key in controlling the intracellular calcium, and little is known about their role in humancancer.METHODS: We used qPCR and pyrosequencing to investigate expression and epigenetic regulation of the calcium channel regulatorysubunit a2d-3 (CACNA2D3) in breast cancer cell lines, primary cancers and metastatic lesions.RESULTS: Expression of CACNA2D3 mRNA is regulated in breast cancer cell lines by methylation in the CpG island located in the50 regulatory region of the gene. Expression is upregulated by azacytidine (AZA) in cells with CpG island methylation but unaffectedin cells lacking methylation. In primary breast carcinomas, methylation is more common in cancers, which subsequently relapsewith loco-regional and, particularly, visceral metastatic disease in both oestrogen receptor-a (ER)-positive and -negative cases.Furthermore, CACNA2D3 CpG island is frequently methylated in breast cancer that has metastasised to the central nervous system.CONCLUSION: Methylation-dependent transcriptional silencing of CACNA2D3 may contribute to the metastatic phenotype of breastcancer. Analysis of methylation in the CACNA2D3 CpG island may have potential as a biomarker for risk of development ofmetastatic disease.

Journal article

Hatzimichael E, Dasoula A, Syed N, Szlosarek PW, Dranitsaris G, Crook T, Briasoulis ECet al., 2012, Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma., 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X

Conference paper

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Syed N, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Thompson A, Crook Tet al., 2012, NT5E promoter methylation is a favorable breast cancer epigenetic biomarker, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472

Journal article

Coley HM, Chivers P, Syed N, Crook Tet al., 2012, Methylated PLK2 predicts response to taxanes, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472

Journal article

Safuwan NAM, Chivers P, Crook T, Syed N, Coley HMet al., 2012, Epigenetics, cell cycle and drug-resistant ovarian cancer, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472

Journal article

Wang H, Lee S, Lo Nigro C, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook Tet al., 2012, NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity, BRITISH JOURNAL OF CANCER, Vol: 106, Pages: 1446-1452, ISSN: 0007-0920

Journal article

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comin A, Merlano M, Quinlan PR, Syed N, Shousha S, Purdie CA, Thompson A, Palmieri C, Crook Tet al., 2011, High frequency of complex TP53 mutations in CNS metastases from breast cancer, British Journal of Cancer

BACKGROUND: Brain metastasis from breast cancer is usually associated with a poor prognosis and early death. Alteration of p53 maycontribute to malignant progression by abrogation of apoptosis induced by oncogene activation and by acquisition of gain-of-functionproperties, which promote tumour aggression. Mutation in TP53 occurs at high frequency in carcinomas of the lung and gastrointestinal tract, but is much less frequent, at 25%, in primary breast cancer. The frequency of TP53 alteration in the central nervoussystem (CNS) metastatic breast cancer is not known.METHODS: In all, 23 cases of histologically confirmed CNS metastatic breast cancer were identified and the coding sequence of TP53determined. TP53 was also sequenced in two control series of primary breast carcinomas from independent clinical centres.RESULTS: We demonstrate a strikingly high frequency of TP53 mutation in the CNS metastatic lesions with an over-representation ofcomplex mutations (non-sense/deletions/insertions). Complex mutations occur in metastatic lesions in both triple-negative breastcancer and hormone receptor/HER2-positive cases. Analysis of paired primary carcinomas and brain metastatic lesions revealedevidence for both clonal selection and generation of new mutations (missense and complex) in progression from a primary breastcarcinoma to brain metastasis.CONCLUSION: Mutation in TP53 is the most common genetic alteration reported during metastasis to the brain in breast cance

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00156737&limit=30&person=true&page=2&respub-action=search.html